- European markets close lower; Novo Nordisk down 20% after obesity drug results CNBC
- Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results Yahoo Finance
- Ozempic maker’s shares plunge after failed weight-loss trial The Telegraph
- Novo Nordisk Shares Plunge After New Obesity Shot Disappoints The Wall Street Journal
- Novo Nordisk Falls Most on Record After New Weight Drug Disappoints Bloomberg
Credit: Source link